Drugs / PEG-CS
PEG-CS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01685853 | Apr 2011 → Mar 2012 | — | European Institute of Oncology | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02040285 | Feb → Jul 2012 | — | Azienda Policlinico Umberto I | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-CS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01685853 ↗ |
| Known as | Lovolesse (PEG-CS) | “Lovolesse (PEG-CS)” NCT02040285 ↗ |
| Known as | Polyethylene glycol with citrate and simethicone | “Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)” NCT01685853 ↗ |